<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00315380</url>
  </required_header>
  <id_info>
    <org_study_id>VCRC5506</org_study_id>
    <nct_id>NCT00315380</nct_id>
  </id_info>
  <brief_title>Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)</brief_title>
  <official_title>Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) is a rare immune system
      disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell)
      in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly
      treat EGPA, it is critical that the level of disease activity can be determined over the
      course of the disease. The purpose of this study is to determine new biological markers, or
      biomarkers, that may be used to assess the severity of this disease in people with EGPA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EGPA, also known as allergic granulomatosis angiitis, is a systemic vasculitis. EGPA is
      marked by three distinct symptoms: asthma; eosinophilia, evidenced by an excessive number of
      eosinophils in the blood and tissues; and vasculitis involving the skin, lungs, nerves,
      kidneys, and other organs. Nerve involvement may also occur in EGPA, causing pain, tingling,
      numbness, and muscle wasting in the hands and feet. Because EGPA patients may not show any
      visible signs of active disease, current methods of monitoring disease progression usually
      represent a period of extended inflammation and disease activity. Thus, patients may go
      untreated during a period of undetectable disease when damage might be preventable. This
      study will use novel scientific methods to identify new biomarkers that can be used to
      monitor disease activity in EGPA patients. These biomarkers may be used to help direct
      clinical care for EGPA patients and assist in future drug development.

      Study visits will occur every 6 months, or annually. Blood and urine collection will occur at
      every visit. A physical exam and medical and medication history will at every visit; also,
      participants will be asked to complete several questionnaires to assess disease activity,
      health status, and tobacco, alcohol, and drug use.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Discover biomarkers in EGPA capable of measuring disease activity and response to treatment</measure>
    <time_frame>Study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the predictive value of biomarkers for clinical outcome in EGPA</measure>
    <time_frame>Study completion.</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Eosinophilic Granulomatosis With Polyangiitis</condition>
  <condition>Churg-Strauss Syndrome</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (serum and plasma), urine, and DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Enrollment
        will be sequential and participants will have disease in various stages and of different
        duration.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for
        the study.

        Parent or guardian willing to provide informed consent, if applicable

        Exclusion Criteria:

        - Inability to give informed consent and to sign the consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A. Merkel, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacklyn Stratton</last_name>
      <email>jstratton1@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Paul A. Monach, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Hughes</last_name>
      <email>Hughes.Samantha@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Ulrich Specks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven R. Ytterberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minnie Singh</last_name>
      <email>singhn4@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Carol A. Langford, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Hopkins</last_name>
      <email>Sarah.Hopkins@Pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Merkel, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica gonzalez</last_name>
      <email>jessica.gonzalez@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Curry Koening, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Messier</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>35873</phone_ext>
      <email>smessier@stjoes.ca</email>
    </contact>
    <investigator>
      <last_name>Nader A. Khalidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Jagadeesh</last_name>
      <email>Samyukta.Jagadeesh@sinaihealth.ca</email>
    </contact>
    <investigator>
      <last_name>Christian Pagnoux, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.org/cms/vcrc/</url>
    <description>Vasculitis Clinical Research Consortium</description>
  </link>
  <link>
    <url>http://rarediseasesnetwork.org/</url>
    <description>Rare Diseases Clinical Research Consortium</description>
  </link>
  <reference>
    <citation>Heeringa P, Schreiber A, Falk RJ, Jennette JC. Pathogenesis of pulmonary vasculitis. Semin Respir Crit Care Med. 2004 Oct;25(5):465-74.</citation>
    <PMID>16088492</PMID>
  </reference>
  <reference>
    <citation>Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity. 2005 Feb;38(1):93-103. Review.</citation>
    <PMID>15804710</PMID>
  </reference>
  <reference>
    <citation>Said G, Lacroix C. Primary and secondary vasculitic neuropathy. J Neurol. 2005 Jun;252(6):633-41. Epub 2005 Apr 5. Review.</citation>
    <PMID>15806339</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 14, 2006</study_first_submitted>
  <study_first_submitted_qc>April 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2006</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Peter Merkel</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>EGPA</keyword>
  <keyword>CSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Churg-Strauss Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

